Feksofenadin

Feksofenadin
Nama sistematis (IUPAC)
	(±)-4-[1-Hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-butyl]-α, α-dimethyl benzeneacetic acid
Data klinis
Nama dagang	Allegra, others
AHFS/Drugs.com	monograph
MedlinePlus	a697035
Data lisensi	US Daily Med:pranala
Kat. kehamilan	B2(AU)
Status hukum	Apotek saja (S2) (AU) OTC (CA) P (UK) OTC (US)
Rute	By mouth
Data farmakokinetik
Bioavailabilitas	30–41%
Ikatan protein	60–70%
Metabolisme	Hepatic (≤5% of dose)
Waktu paruh	14.4 hours
Ekskresi	Feces (~80%) and urine (~10%) as unchanged drug
Pengenal
Nomor CAS	83799-24-0
Kode ATC	R06AX26
PubChem	CID 3348
Ligan IUPHAR	4819
DrugBank	DB00950
ChemSpider	3231
UNII	E6582LOH6V
KEGG	D07958
ChEBI	CHEBI:5050
ChEMBL	CHEMBL914
Data kimia
Rumus	C32H39NO4
	InChI InChI=1S/C32H39NO4/c1-31(2,30(35)36)25-17-15-24(16-18-25) 29(34)14-9-21-33-22-19-28(20-23-33)32(37, 26-10-5-3-6-11-26)27-12-7-4-8-13-27/h3-8, 10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36) ; Key:RWTNPBWLLIMQHL-UHFFFAOYSA-N ;

Feksofenadin^[3] adalah obat antihistamin yang digunakan dalam pengobatan gejala alergi, seperti rinitis alergi dan urtikaria.^[4]

Secara terapeutik, feksofenadin adalah penghambat H₁ perifer selektif. Obat ini diklasifikasikan sebagai antihistamin generasi kedua karena kurang mampu melewati sawar darah otak dan menyebabkan sedasi, dibandingkan antihistamin generasi pertama.^[5]^[6]

Obat ini dipatenkan pada tahun 1979 dan mulai digunakan secara medis pada tahun 1996.^[7] Obat ini ada dalam Daftar Obat Esensial Organisasi Kesehatan Dunia.^[8] Feksofenadin telah diproduksi dalam bentuk generik sejak 2011.^[9]

Sejarah

kegunaan dalam Medis

Efek Samping

Overdosis

Farmakologi

Interaksi

Referensi

^ Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Houston B, Oosterhuis B, Bjerrum OJ, Rowland M, Garner C (May 2010). "Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability". European Journal of Pharmaceutical Sciences. 40 (2): 125–131. doi:10.1016/j.ejps.2010.03.009. PMID 20307657.
^ ^a ^b ^c Smith SM, Gums JG (July 2009). "Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders". Expert Opinion on Drug Metabolism & Toxicology. 5 (7): 813–822. doi:10.1517/17425250903044967. PMID 19545214.
^ Kesalahan pengutipan: Tag <ref> tidak sah; tidak ditemukan teks untuk ref bernama Brands
^ Bachert C (May 2009). "A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis". Clinical Therapeutics. 31 (5): 921–944. doi:10.1016/j.clinthera.2009.05.017. PMID 19539095.
^ Compalati E, Baena-Cagnani R, Penagos M, Badellino H, Braido F, Gómez RM, Canonica GW, Baena-Cagnani CE (2011). "Systematic review on the efficacy of fexofenadine in seasonal allergic rhinitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials". International Archives of Allergy and Immunology. 156 (1): 1–15. doi:10.1159/000321896  . PMID 21969990.
^ Dicpinigaitis PV, Gayle YE (November 2003). "Effect of the second-generation antihistamine, fexofenadine, on cough reflex sensitivity and pulmonary function". British Journal of Clinical Pharmacology. 56 (5): 501–504. doi:10.1046/j.1365-2125.2003.01902.x. PMC 1884387  . PMID 14651723.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. hlm. 548. ISBN 9783527607495.
^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533  . WHO/MHP/HPS/EML/2021.02.
^ "Dr. Reddy's announces the launch of Over-the-Counter Fexofenadine HCl and Pseudoephedrine HCl extended release tablets". Dr. Reddy's Laboratories Ltd. 30 August 2011. Diarsipkan dari versi asli tanggal 12 October 2016. Diakses tanggal 27 May 2016.

[1] Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Houston B, Oosterhuis B, Bjerrum OJ, Rowland M, Garner C (May 2010). "Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability". European Journal of Pharmaceutical Sciences. 40 (2): 125–131. doi:10.1016/j.ejps.2010.03.009. PMID 20307657.

[phk09-2] Smith SM, Gums JG (July 2009). "Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders". Expert Opinion on Drug Metabolism & Toxicology. 5 (7): 813–822. doi:10.1517/17425250903044967. PMID 19545214.

[Brands-3] Kesalahan pengutipan: Tag <ref> tidak sah; tidak ditemukan teks untuk ref bernama Brands

[4] Bachert C (May 2009). "A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis". Clinical Therapeutics. 31 (5): 921–944. doi:10.1016/j.clinthera.2009.05.017. PMID 19539095.

[rhin11-5] Compalati E, Baena-Cagnani R, Penagos M, Badellino H, Braido F, Gómez RM, Canonica GW, Baena-Cagnani CE (2011). "Systematic review on the efficacy of fexofenadine in seasonal allergic rhinitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials". International Archives of Allergy and Immunology. 156 (1): 1–15. doi:10.1159/000321896  . PMID 21969990.

[rhin1-6] Dicpinigaitis PV, Gayle YE (November 2003). "Effect of the second-generation antihistamine, fexofenadine, on cough reflex sensitivity and pulmonary function". British Journal of Clinical Pharmacology. 56 (5): 501–504. doi:10.1046/j.1365-2125.2003.01902.x. PMC 1884387  . PMID 14651723.

[Fis2006-7] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. hlm. 548. ISBN 9783527607495.

[WHO22nd-8] World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533  . WHO/MHP/HPS/EML/2021.02.

[9] "Dr. Reddy's announces the launch of Over-the-Counter Fexofenadine HCl and Pseudoephedrine HCl extended release tablets". Dr. Reddy's Laboratories Ltd. 30 August 2011. Diarsipkan dari versi asli tanggal 12 October 2016. Diakses tanggal 27 May 2016.

[3]

[4]

[1]

[2]

[5]

[6]

[7]

[8]

[9]